Medtronic has completed the acquisition of CathWorks, a company specialising in advancing the diagnosis and treatment of coronary artery disease (CAD), for $585m, with further undisclosed earn-out payments possible after the deal.
The acquisition expands Medtronic’s cardiovascular disease product portfolio.
In February 2026, the company announced its intention to acquire CathWorks.
The move follows a 2022 strategic partnership and co-promotion agreement for the CathWorks FFRangio system, currently available commercially in Europe, Japan and the US.
The FFRangio System uses AI and computational science for the physiological assessment of the coronary arteries.
The latest announcement follows one-year results from CathWorks’ ALL-RISE randomised control trial, shared at the 2026 American College of Cardiology conference.
This trial enrolled more than 1,900 patients at 59 sites spanning Asia, Europe, the Middle East, and North America.
Medtronic stated that the acquisition aligns with its strategy to advance its position through targeted mergers and acquisitions and to provide long-term value for its partners in the healthcare sector.
It anticipates the transaction will have minimal impact on its fiscal year 2027 GAAP and adjusted earnings per share, with results becoming neutral or accretive in subsequent years.
CathWorks president and CEO Ramin Mousavi said: “With the acquisition of CathWorks by Medtronic, we are boldly redefining the future of cardiovascular care. As I reflect on our long-term partnership, I am deeply grateful and proud of what we’ve accomplished together.
“This deal is a testament to CathWorks’ and Medtronic’s shared commitment, vision, and relentless drive to revolutionise the cath lab and deliver better solutions for patients living with cardiovascular disease. Together, we have ushered in a new dawn in cardiovascular diagnosis and patient outcomes.”
